01 October 2020 | News
Taigexyn® is a novel safe and effective antibiotic for the treatment of bacterial infections including those caused by drug-resistant bacteria
Image credit- shutterstock.com
TaiGen Biotechnology Company in Taiwan has signed an exclusive licensing agreement with Luminarie Canada Inc., a leading Canadian pharmaceutical company, to develop and commercialize Taigexyn® (nemonoxacin) in Canada, Australia and New Zealand.
Taigexyn® is a novel safe and effective antibiotic for the treatment of bacterial infections including those caused by drug-resistant bacteria.
Under the terms of the agreement, Luminarie will be responsible for the development, registration and commercialization of Taigexyn® in the territory and assume all associated costs. The territory includes Canada, Australia and New Zealand.
In exchange for the exclusive rights, TaiGen will receive the additional regulatory and commercial milestones in the future. Luminarie will purchase Taigexyn® at a pre-negotiated price from TaiGen for its commercialization in the territory.
Yanick Thibeault, President-Owner of Luminarie Canada, said "We're pleased to develop a long-term partnership with TaiGen, an experienced developer of novelty drugs with Global manufacturing standards, and to offer Taigexyn® to our patients and customers. Taigexyn® will support our vision to bring novel products for unmet medical needs."
Kuo-Lung Huang, Chairman and Chief Executive Officer of Licensor, said, "We are interested in Luminarie because we share the same innovative vision for Taigexyn®. By partnering with Luminarie, TaiGen will be able to tap into these developed markets with Taigexyn® where the need for such a novel antibiotic to treat drug-resistant infection is very high."